A Randomized, Open Label, Parallel Group, Study of the Impact of Aripiprazole (Abilify) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism

Trial Profile

A Randomized, Open Label, Parallel Group, Study of the Impact of Aripiprazole (Abilify) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Aripiprazole (Primary) ; Antipsychotics
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Otsuka America Pharmaceutical
  • Most Recent Events

    • 09 Nov 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2017.
    • 02 Dec 2014 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov record.
    • 16 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top